Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kenet

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 3, 2009
Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitorsG Kenet, A Lubetsky, J Luboshitz, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2007
Clinical trial: evaluation of a clinical decision-support model for upper abdominal complaints in primary-care practiceN Horowitz, M Moshkowitz, M Leshno, et al.
The Journal of Trauma|September 6, 2001
Recombinant activated factor VII for adjunctive hemorrhage control in traumaU Martinowitz, G Kenet, E Segal, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 30, 2002
Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experienceA Lubetsky, U Martinowitz, J Luboshitz, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 7, 2011
Thrombocytopenia and bleeding in dental procedures of patients with Gaucher diseaseN Givol, G Goldstein, O Peleg, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 21, 2011
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIIB Sørensen, Y Dargaud, G Kenet, et al.
Gastroenterology|October 1, 1992
Bromobenzene accelerates hepatocyte streaming in ratsN Arber, G Zajicek, R Shamir, et al.
Alimentary Pharmacology & Therapeutics|April 1, 1997
Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitisR Oren, Y Maaravi, F Karmeli, et al.
Thrombosis and Haemostasis|March 4, 1999
Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand diseaseA Lubetsky, S Schulman, D Varon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 23, 2017
Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxisG Kenet, A Oladapo, J D Epstein, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 3, 2009
Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitorsG Kenet, A Lubetsky, J Luboshitz, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2007
Clinical trial: evaluation of a clinical decision-support model for upper abdominal complaints in primary-care practiceN Horowitz, M Moshkowitz, M Leshno, et al.
The Journal of Trauma|September 6, 2001
Recombinant activated factor VII for adjunctive hemorrhage control in traumaU Martinowitz, G Kenet, E Segal, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 30, 2002
Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experienceA Lubetsky, U Martinowitz, J Luboshitz, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 7, 2011
Thrombocytopenia and bleeding in dental procedures of patients with Gaucher diseaseN Givol, G Goldstein, O Peleg, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 21, 2011
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIIB Sørensen, Y Dargaud, G Kenet, et al.
Gastroenterology|October 1, 1992
Bromobenzene accelerates hepatocyte streaming in ratsN Arber, G Zajicek, R Shamir, et al.
Alimentary Pharmacology & Therapeutics|April 1, 1997
Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitisR Oren, Y Maaravi, F Karmeli, et al.
Thrombosis and Haemostasis|March 4, 1999
Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand diseaseA Lubetsky, S Schulman, D Varon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 23, 2017
Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxisG Kenet, A Oladapo, J D Epstein, et al.
Pageof 10